MX391279B - Anticuerpos biespecíficos contra cd3 y cd20. - Google Patents

Anticuerpos biespecíficos contra cd3 y cd20.

Info

Publication number
MX391279B
MX391279B MX2017008875A MX2017008875A MX391279B MX 391279 B MX391279 B MX 391279B MX 2017008875 A MX2017008875 A MX 2017008875A MX 2017008875 A MX2017008875 A MX 2017008875A MX 391279 B MX391279 B MX 391279B
Authority
MX
Mexico
Prior art keywords
bispecific antibodies
antibodies against
diseases
cell
treatment
Prior art date
Application number
MX2017008875A
Other languages
English (en)
Spanish (es)
Other versions
MX2017008875A (es
Inventor
David Satijn
Den Brink Edward Van
Esther Breij
Isil Altintas
Janine Schuurman
Patrick Engelberts
Paul Parren
Riemke Van Dijkhuizen Radersma
Rik Rademaker
Sandra Verploegen
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56355550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX391279(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2015/050276 external-priority patent/WO2015104346A1/en
Application filed by Genmab As filed Critical Genmab As
Publication of MX2017008875A publication Critical patent/MX2017008875A/es
Publication of MX391279B publication Critical patent/MX391279B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
MX2017008875A 2015-01-08 2016-01-08 Anticuerpos biespecíficos contra cd3 y cd20. MX391279B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
PCT/EP2015/050276 WO2015104346A1 (en) 2014-01-09 2015-01-08 Humanized or chimeric cd3 antibodies
DKPA201500413 2015-07-15
DKPA201500412 2015-07-15
DKPA201500415 2015-07-16
DKPA201500416 2015-07-16
PCT/EP2016/050296 WO2016110576A1 (en) 2015-01-08 2016-01-08 Bispecific antibodies against cd3 and cd20

Publications (2)

Publication Number Publication Date
MX2017008875A MX2017008875A (es) 2017-09-27
MX391279B true MX391279B (es) 2025-03-21

Family

ID=56355550

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017008875A MX391279B (es) 2015-01-08 2016-01-08 Anticuerpos biespecíficos contra cd3 y cd20.
MX2022004082A MX2022004082A (es) 2015-01-08 2017-07-04 Anticuerpos biespecificos contra cd3 y cd20.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022004082A MX2022004082A (es) 2015-01-08 2017-07-04 Anticuerpos biespecificos contra cd3 y cd20.

Country Status (13)

Country Link
US (2) US10544220B2 (cg-RX-API-DMAC7.html)
EP (1) EP3242682A1 (cg-RX-API-DMAC7.html)
JP (3) JP6853176B2 (cg-RX-API-DMAC7.html)
KR (3) KR20240148942A (cg-RX-API-DMAC7.html)
CN (2) CN107660214B (cg-RX-API-DMAC7.html)
AU (3) AU2016205967B2 (cg-RX-API-DMAC7.html)
CA (1) CA2973159A1 (cg-RX-API-DMAC7.html)
EA (1) EA201791554A1 (cg-RX-API-DMAC7.html)
IL (3) IL289946B2 (cg-RX-API-DMAC7.html)
MX (2) MX391279B (cg-RX-API-DMAC7.html)
SG (1) SG11201705496SA (cg-RX-API-DMAC7.html)
UA (1) UA120286C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016110576A1 (cg-RX-API-DMAC7.html)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201815863T4 (tr) * 2010-11-30 2018-11-21 Chugai Pharmaceutical Co Ltd Sitotoksisiteyi indükleyen terapötik madde.
AU2013285355A1 (en) 2012-07-06 2015-01-29 Genmab B.V. Dimeric protein with triple mutations
IL311371B2 (en) 2013-07-05 2024-09-01 Genmab As CD3 antibodies of human origin or chimeras
CN106029696B (zh) 2013-12-17 2020-07-28 基因泰克公司 抗cd3抗体及使用方法
TW201625690A (zh) 2014-09-12 2016-07-16 建南德克公司 抗－ｃｌｌ－１抗體及免疫結合物
JP2018526972A (ja) 2015-06-16 2018-09-20 ジェネンテック， インコーポレイテッド 抗ｃｄ３抗体及び使用方法
PE20240218A1 (es) 2015-06-16 2024-02-16 Genentech Inc Anticuerpos madurados por afinidad y humanizados para fcrh5
JP6996983B2 (ja) 2015-06-16 2022-02-21 ジェネンテック， インコーポレイテッド 抗ｃｌｌ－１抗体及び使用方法
BR112018000696A2 (pt) 2015-07-15 2018-09-18 Genmab As ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit?
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EP3252078A1 (en) * 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
AU2018276419A1 (en) * 2016-06-02 2019-10-17 F. Hoffmann-La Roche Ag Type II anti-CD20 antibody and anti-CD20/CD3 bispecific antibody for treatment of cancer
JP7083819B2 (ja) * 2016-09-30 2022-06-13 セントレ ナショナル デ ラ レセルシュ シャンティフィク 細胞マーカー
US11466094B2 (en) 2016-11-15 2022-10-11 Genentech, Inc. Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
WO2018114748A1 (en) 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
CN119019564A (zh) * 2017-08-01 2024-11-26 Ab工作室有限公司 双特异性抗体及其用途
CN111406067B (zh) 2017-08-04 2022-11-08 健玛保 与pd-l1和cd137结合的结合剂及其用途
EP3668898B1 (en) * 2017-08-14 2023-07-05 MorphoSys AG Humanized antibodies for cd3
CN107501412A (zh) * 2017-10-11 2017-12-22 深圳精准医疗科技有限公司 突变型双特异性抗体及其应用
CN118772288A (zh) 2018-02-08 2024-10-15 豪夫迈·罗氏有限公司 双特异性抗原结合分子和使用方法
BR112020015052A2 (pt) * 2018-02-09 2020-12-08 Genmab A/S Composição farmacêutica, uso da composição farmacêutica, métodos para tratar câncer em um sujeito, para preparar uma composição farmacêutica e para preparar uma forma de dosagem unitária, forma de dosagem unitária, recipiente, e, kit-de-partes
CA3093330A1 (en) 2018-03-14 2019-09-19 Novimmune Sa Anti-cd3 epsilon antibodies and methods of use thereof
EP3569617A1 (en) * 2018-05-18 2019-11-20 Trion Research GmbH Pharmaceutical preparation for use in treating epstein- barr virus positive patients with reactivation phenomenon- associated diseases
CN110540593B (zh) * 2018-05-29 2022-05-17 上海药明生物技术有限公司 新型的抗cd3/抗cd20双特异性抗体
US12129298B2 (en) * 2018-06-21 2024-10-29 Daiichi Sankyo Company, Limited Compositions including CD3 antigen binding fragments and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN109836502B (zh) * 2018-11-12 2021-09-07 浙江大学 一种双特异性抗体及其应用
US12463463B2 (en) 2019-01-28 2025-11-04 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
CN116178547A (zh) * 2019-02-22 2023-05-30 武汉友芝友生物制药股份有限公司 Cd3抗原结合片段及其应用
EP3969907B1 (en) * 2019-05-13 2025-09-24 F. Hoffmann-La Roche AG Interference-suppressed pharmacokinetic immunoassay
CN110551221B (zh) * 2019-07-02 2021-03-05 广州爱思迈生物医药科技有限公司 一种双特异性抗体及其制备方法与应用
BR112022002653A2 (pt) 2019-08-15 2022-05-03 Genmab As Composição farmacêutica, uso da composição farmacêutica, métodos para tratar câncer, para preparar uma composição farmacêutica e para preparar uma forma de dosagem unitária, forma de dosagem unitária, recipiente, e, kit de partes
CN111100204B (zh) * 2019-11-26 2022-03-11 山东立菲生物产业有限公司 靶向cd20的抗体、其制备方法和应用
AR120741A1 (es) 2019-12-13 2022-03-16 Genentech Inc Anticuerpos anti-ly6g6d y métodos de uso
EP4090377A1 (en) * 2020-01-13 2022-11-23 Synaffix B.V. Conjugates of antibodies an immune cell engagers
CN113402612A (zh) * 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
CN115298221A (zh) 2020-03-18 2022-11-04 健玛保 结合b7h4的抗体
CN115916166A (zh) 2020-05-08 2023-04-04 健玛保 针对cd3和cd20的双特异性抗体
US11976120B2 (en) * 2020-06-01 2024-05-07 Boehringer Ingelheim International Gmbh Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US10981996B1 (en) * 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
CN112062855B (zh) * 2020-08-26 2024-08-30 北京天诺健成医药科技有限公司 一种含有衔接器的药物治疗剂的开发和应用
CA3192251A1 (en) * 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
CN116406293A (zh) * 2020-09-10 2023-07-07 健玛保 用于治疗滤泡性淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体
CA3190349A1 (en) 2020-09-10 2022-03-17 Brian Elliott Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
CN116782933A (zh) * 2020-09-10 2023-09-19 健玛保 用于治疗弥漫性大b细胞淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体
BR112023004351A2 (pt) 2020-09-10 2023-04-04 Genmab As Método para tratar linfoma folicular em um sujeito humano
JP2023542092A (ja) * 2020-09-10 2023-10-05 ジェンマブ エー／エス びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
WO2022098638A2 (en) 2020-11-04 2022-05-12 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
JP7716473B2 (ja) 2020-11-04 2025-07-31 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
CN114656562B (zh) * 2020-12-23 2023-11-03 北京天广实生物技术股份有限公司 结合人和猴cd3的抗体及其应用
KR20230157315A (ko) 2021-01-28 2023-11-16 리제너론 파마슈티칼스 인코포레이티드 사이토카인 방출 증후군을 치료하기 위한 조성물 및 방법
WO2022192895A1 (en) * 2021-03-10 2022-09-15 H. Lee Moffitt Cancer Center And Research Institute Inc. Compositions and methods to reduce therapeutic t cell toxicity
KR20230156921A (ko) * 2021-03-12 2023-11-15 젠맵 에이/에스 비-활성화 항체 변이체
AU2021443318A1 (en) 2021-04-30 2023-09-07 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
CA3218578A1 (en) 2021-05-14 2022-11-17 Carol Elaine O'hear Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
WO2023144290A1 (en) 2022-01-28 2023-08-03 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
JP2025503177A (ja) 2022-01-28 2025-01-30 ジェンマブ エー／エス びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
IL316002A (en) 2022-04-11 2024-11-01 Regeneron Pharma Compositions and methods for universal tumor cell killing
WO2023198839A2 (en) 2022-04-13 2023-10-19 Genmab A/S Bispecific antibodies against cd3 and cd20
WO2023201291A1 (en) 2022-04-13 2023-10-19 Genentech, Inc. Pharmaceutical compositions of mosunetuzumab and methods of use
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
IL321437A (en) * 2022-12-14 2025-08-01 Evolveimmune Therapeutics Inc Bispecific antibody fusion molecules and methods for using them
EP4665385A2 (en) 2023-02-17 2025-12-24 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies
EP4626447A1 (en) 2023-03-31 2025-10-08 AbelZeta Inc. Bispecific chimeric antigen receptors targeting cd20 and bcma
KR20250169618A (ko) 2023-04-13 2025-12-03 젠맵 에이/에스 Cd3 및 cd20에 대한 이중특이적 항체를 사용하여 림프종을 치료하는 방법
US20240400685A1 (en) 2023-05-15 2024-12-05 Genmab A/S Highly purified epcoritamab compositions
US20240409656A1 (en) 2023-05-15 2024-12-12 Genmab A/S Methods of treating cd20 expressing b-cell cancers
WO2025064890A1 (en) * 2023-09-20 2025-03-27 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof
WO2025109119A1 (en) * 2023-11-22 2025-05-30 Priothera Sas Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators
GB2641580A (en) 2024-06-07 2025-12-10 T Therapeutics Ltd Tumour-transforming multispecific proteins

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1558648E (pt) * 2002-10-17 2012-04-23 Genmab As Anticorpos monoclonais humanos contra cd20
WO2007042261A2 (en) 2005-10-11 2007-04-19 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
US20100291023A1 (en) * 2007-05-31 2010-11-18 Genmab A/S Method for extending the half-life of exogenous or endogenous soluble molecules
EP2170951A2 (en) 2007-05-31 2010-04-07 Genmab A/S Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering
AU2008255350B2 (en) 2007-05-31 2014-07-10 Genmab A/S Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
CA2738568C (en) * 2008-10-01 2024-02-20 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
TW201109438A (en) 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011090762A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Heterodimer binding proteins and uses thereof
CA2796181C (en) * 2010-04-20 2023-01-03 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
TR201815863T4 (tr) * 2010-11-30 2018-11-21 Chugai Pharmaceutical Co Ltd Sitotoksisiteyi indükleyen terapötik madde.
CN103796677B (zh) * 2011-04-20 2019-08-16 健玛保 针对her2和cd3的双特异性抗体
CN107722124A (zh) * 2011-05-21 2018-02-23 宏观基因有限公司 能够与人和非人cd3结合的cd3结合分子
EA030147B1 (ru) 2011-08-23 2018-06-29 Роше Гликарт Аг Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
AU2013285355A1 (en) 2012-07-06 2015-01-29 Genmab B.V. Dimeric protein with triple mutations
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
EP2961770A1 (en) 2013-02-26 2016-01-06 Roche Glycart AG Bispecific t cell activating antigen binding molecules
WO2014131694A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
IL311371B2 (en) 2013-07-05 2024-09-01 Genmab As CD3 antibodies of human origin or chimeras
JP2016531100A (ja) * 2013-07-12 2016-10-06 ザイムワークス，インコーポレイテッド 二重特異的なｃｄ３及びｃｄ１９抗原結合構築物
CN106029696B (zh) * 2013-12-17 2020-07-28 基因泰克公司 抗cd3抗体及使用方法
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
LT3699198T (lt) 2014-11-17 2025-05-12 Regeneron Pharmaceuticals, Inc. Būdai navikams gydyti naudojant cd3×cd20 bispecifinį antikūną
WO2017210485A1 (en) 2016-06-01 2017-12-07 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma
EP3668898B1 (en) * 2017-08-14 2023-07-05 MorphoSys AG Humanized antibodies for cd3
CN116406293A (zh) * 2020-09-10 2023-07-07 健玛保 用于治疗滤泡性淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体

Also Published As

Publication number Publication date
IL318350A (en) 2025-03-01
EA201791554A1 (ru) 2017-12-29
IL289946A (en) 2022-03-01
KR20240148942A (ko) 2024-10-11
KR102712786B1 (ko) 2024-10-04
JP7177317B2 (ja) 2022-11-24
CN107660214A (zh) 2018-02-02
AU2022200871B2 (en) 2025-05-08
AU2016205967B2 (en) 2021-11-11
AU2025213616A1 (en) 2025-08-21
IL289946B1 (en) 2025-02-01
EP3242682A1 (en) 2017-11-15
IL289946B2 (en) 2025-06-01
BR112017014551A2 (pt) 2018-05-15
JP2023002615A (ja) 2023-01-10
US10544220B2 (en) 2020-01-28
JP6853176B2 (ja) 2021-03-31
US20170355767A1 (en) 2017-12-14
CN114478792A (zh) 2022-05-13
AU2016205967A1 (en) 2017-07-27
US20200199231A1 (en) 2020-06-25
IL253166A0 (en) 2017-08-31
SG11201705496SA (en) 2017-08-30
AU2022200871A1 (en) 2022-03-03
CN107660214B (zh) 2022-02-08
KR20170128222A (ko) 2017-11-22
IL253166B (en) 2022-02-01
JP2018508188A (ja) 2018-03-29
CA2973159A1 (en) 2016-07-14
MX2022004082A (es) 2022-05-03
UA120286C2 (uk) 2019-11-11
JP7596342B2 (ja) 2024-12-09
NZ733531A (en) 2024-11-29
KR20240064746A (ko) 2024-05-13
JP2021104020A (ja) 2021-07-26
WO2016110576A1 (en) 2016-07-14
KR102663073B1 (ko) 2024-05-07
MX2017008875A (es) 2017-09-27

Similar Documents

Publication Publication Date Title
MX391279B (es) Anticuerpos biespecíficos contra cd3 y cd20.
CL2018000422A1 (es) Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos
CO2018001149A2 (es) Anticuerpos monoclonales contra bcma
CL2018000819A1 (es) Anticuerpos biespecíficos anti-cd20 humano/receptor de transferrina humano y métodos para su uso
GT201700188A (es) Anticuerpos contra tau y sus usos
DOP2016000315A (es) Anticuerpos monoclonales contra el epítope de her2 y sus métodos de uso
MX391051B (es) Anticuerpos anti-cd47 y usos de los mismos.
SV2017005355A (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
CL2017000885A1 (es) Anticuerpos anti-ox40 humanizados y usos de los mismos
MX387587B (es) Formulaciones subcutáneas de anticuerpos anti-cd38 y sus usos.
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
MX391171B (es) Anticuerpos anti-cd19 humano con alta afinidad
MX2018004515A (es) Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
MX2020004503A (es) Anticuerpos cd3 humanizados o quimericos.
MX370018B (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
MX2016009428A (es) Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.
MX2018004121A (es) Receptores de antigeno y usos de los mismos.
EA201691473A1 (ru) Биспецифические анти-il-13/il-17 антитела и их применение
MX2017006167A (es) Compuestos que interactúan con glicanos y métodos de uso.
CO2019009787A2 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos
MX2018003700A (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de higado graso, y uso de los mismos.
CL2017001135A1 (es) Anticuerpos mejorados contra il-6
MX2023006415A (es) Anticuerpos, usos y metodos.
AR101671A1 (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso